Key result
Mavacamten significantly reduced the proportion of patients still meeting guideline criteria for septal reduction therapy at 16 weeks compared with placebo (17.9% vs 76.8%, p<0.001).
Absolute Event Rate: 17.9% vs 76.8%
p-value: p=<0.001
This editorial discusses the current evidence and future potential applications of mavacamten, a novel cardiac myosin inhibitor, as an alternative to septal reduction therapy for symptomatic obstructive hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) is a common heridetary cardiac disorder characterized by a wide range of symptoms. The pharmacological treatment of HCM is currently limited to beta blockers, non-dihydropyridine calcium channel blockers and disopyramide. Mavacamten is a novel cardiac myosin inhibitor, which was recently added to the limited pharmacological list of treatment options for HCM. This editorial elaborates on current evidence evaluating the use of mavacamten in patients with symptomatic obstructive HCM, comments on its current use and its expanded potential applications in the future.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2023) conducted an editorial in symptomatic obstructive hypertrophic cardiomyopathy (n=112). Mavacamten vs. Placebo was evaluated on patients still meeting the guideline criteria for septal reduction therapy (SRT) (p=<0.001). Mavacamten significantly reduced the proportion of patients still meeting guideline criteria for septal reduction therapy at 16 weeks compared with placebo (17.9% vs 76.8%, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: